Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

APT and Atreus announce strategic R&D agreement
November 2007
SHARING OPTIONS:

BOSTON—Advanced Proteome Therapeutics Inc. (APT), a subsidiary of Advanced Proteome Therapeutics Corp., and Atreus Pharmaceuticals Inc. recently announced they have entered into a strategic research and development agreement for novel protein in vivo imaging agents using advanced site-directed peptide modification techniques developed by APT.

The first product target is intended for imaging the earliest changes associated with rheum-atoid arthritis. Under the deal, Atreus will have the exclusive right to commercialize the jointly developed agents in return for revenue-sharing payments to APT. Atreus will provide technical, clinical and market expertise to the program, as well as intellectual property rights.

 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.